Skip to main content
AmigoFish

Episode 403: Pharmacology 101: Checkpoint Inhibitors

From The ONS Podcast · · 34 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

"Because the premise of immune checkpoint blockade centers around elevating the immune function, we should always take a great deal of caution around those patients who have high immune risks. Those include patients with autoimmune disorders. That's one of our biggest questions that we ask, usually every consult that we're seeing with solid tumor. 'Do you have any history of autoimmune disorders? Tell me a little bit more about it. Is it being treated? What are your symptoms like?' And then also patients who have undergone organ transplants. Now, interestingly, this does include stem cell transplants," Kelsey Finch, PharmD, BCOP, oncology pharmacist practitioner at Columbus Regional Health in Indiana, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about checkpoint inhibitors.

Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod

Licensed under Creative Commons by Attribution 3.0

Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 20, 2027. Kelsey Finch has disclosed a speakers bureau relationship with AstraZeneca. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Learning outcome: Learners will report an increase in knowledge related to checkpoint inhibitors in the treatment of cancer.

Episode Notes

- Complete this evaluation for free NCPD.

- ONS Podcast™ episodes: - Pharmacology 101 series

- Episode 273: Updates in Chemotherapy and Immunotherapy

- Episode 174: Administer Pembrolizumab Immunotherapy With Confidence

- Episode 139: How CAR and Other T Cells Are Revolutionizing Cancer Treatment

- ONS Voice articles: - Here's Why Oncology Nurses Are Pivotal in Managing Immune-Related Adverse Events

- Make Subcutaneous Administration More Comfortable for Your Patients

- Nursing Considerations for ICI-Related Myocarditis

- Oncology Nurses Navigate the Changing Landscape of Immuno-Oncology

- Postdischarge ICI Patient Education Eliminates Hospital Readmissions

- Shorter Administration Times Still Require High-Acuity Care

- ONS Voice oncology drug reference sheets: - Dostarlimab-Gxly

- Nivolumab and Hyaluronidase-Nvhy

- Nivolumab and Relatlimab-Rmbw

- Pembrolizumab and Berahyaluronidase Alfa-Pmph

- Retifanlimab-Dlwr

- Toripalimab-Tpzi

- ONS books: - Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition)

- Guide to Cancer Immunotherapy (second edition)

- ONS course: ONS/ONCC® Chemotherapy Immunotherapy Certificate™

- Clinical Journal of Oncology Nursing articles: - Immune Checkpoint Inhibitor–Related Myocarditis: Recognition, Surveillance, and Management

- Immune Checkpoint Inhibitor Therapy: Key Principles When Educating Patients

- Triple M Syndrome: Implications for Hematology-Oncology Advanced Practice Providers

- ONS Huddle Cards: - Checkpoint Inhibitors

- Immunotherapy

- ONS Learning Libraries: - Genomics and Precision Oncology Learning Library

- Immuno-Oncology Learning Library

- Drugs@FDA package inserts

- National Comprehensive Cancer Network homepage (https://www.nccn.org/)

- OncoLink: All About Immunotherapy

To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/).

To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.

To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.

Highlights From This Episode

"Before immune checkpoint blockade, the two-year overall survival rate in metastatic melanoma was hovering around 10%. After these agents came to market, depending on the trial and the agents used, that number actually…

Back to The ONS Podcast · Report a problem